H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on ALX Oncology to $4 from $2 and keeps a Buy rating on the shares. The firm says the next major catalyst for the shares is the ALX2004 safety data in the second half of 2026. There is potential for ALX2004 to be different from other EGFR antibody-drug conjugates in terms of safety, the analyst tells investors in a research note.
